Therapeutic Interchange as a Cost-Containment Measure Louis E. Achusim Correspondence 06 December 2012 Pages: 347 - 351
The Australian Guidelines for Subsidisation of Pharmaceuticals Magnus Johannesson Leading Article 06 December 2012 Pages: 355 - 362
Medicaid Drug Utilisation Review Under OBRA 1990 Thomas R. FuldaSteven L. Hass Leading Article 06 December 2012 Pages: 363 - 370
Optimising the Economic Efficiency of Drug Studies Mary Ellen Kitler Review Article 06 December 2012 Pages: 371 - 387
The Costs and Benefits of Switching a Drug from Prescription-Only to Over-the-Counter Status Fredrik AnderssonEvridiki Hatziandreu Review Article 06 December 2012 Pages: 388 - 396
Clinical and Economic Evaluation of Benzodiazepines John S. LyonsDavid B. LarsonJoseph Hromco Review Article 06 December 2012 Pages: 397 - 407
The Economic Impact of HA-1A (Centoxin) Against Endotoxin Steven L. Barriere Original Research Article 06 December 2012 Pages: 408 - 413
Effect of Biological and Analytical Variation in Cholesterol Measurement on the Cost-Effectiveness of Cholesterol-Lowering Therapy Léon L. Martens Original Research Article 06 December 2012 Pages: 414 - 421
The Australian Guidelines for Subsidisation of Pharmaceuticals David A. HenryMagnus Johannesson Correspondence 06 December 2012 Pages: 422 - 426
Is Alteplase (t-PA) More Cost-Effective than Streptokinase? Lisa A. Sanchez Current Comment 06 December 2012 Pages: 427 - 428
Who Uses Streptokinase vs Alteplase (t-PA), and Why? Lisa A. Sanchez Current Comment 06 December 2012 Pages: 428 - 429
Glossary of Terms Used in Pharmacoeconomic and Quality of Life Analyses OriginalPaper 06 December 2012 Pages: 430 - 432
